Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kalvista Pharmaceuticals Inc (NQ: KALV )

9.325 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kalvista Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Recap: KalVista Pharma Q3 Earnings
Via Benzinga
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
From KalVista Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday?
Results from KalVista Pharmaceuticals' Phase 3 KONFIDENT trial. Sebetralstat, an oral on-demand therapy, shows efficacy for hereditary angioedema. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Insiders Buying Monro And 3 Other Stocks
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.